LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis - PubMed (original) (raw)
LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis
G N Thalmann et al. Prostate. 2000.
Abstract
Background: Clinically, the lethal phenotypes of human prostate cancer are characterized by their progression to androgen-independence and their propensity to form osseous metastases. We reported previously on the establishment of androgen-independent (AI) human prostate cancer cell lines derived from androgen-dependent (AD) LNCaP cells, with androgen independence defined as the capability of prostate cancer cells to grow in castrated hosts. One of the sublines, C4-2, was found to be AI, highly tumorigenic, and metastatic, having a proclivity for metastasis to the bone.
Methods: We established the AI and bone metastatic cell sublines B2, B3, B4, and B5 from the parental C4-2 subline, using a previously established coinoculating procedure. We determined the biologic behavior of the parental and derivative LNCaP sublines in vivo and in vitro, as well as their molecular and cytogenetic characteristics.
Results: Unlike other human prostate cancer models, the LNCaP progression model shares remarkable similarities with human prostate cancer. We observed a comparable pattern of metastasis from the primary to the lymph node and to the axial skeleton, with a predominant phenotype of osteoblastic reaction; 25-37.5% of the animals developed paraplegia. Cytogenetic and biochemical characterizations of LNCaP sublines also indicate close similarities between human prostate cancer and the LNCaP progression model. Additional chromosomal changes were detected in B2-B5 sublines derived from C4-2 bone metastases. These LNCaP sublines were found to grow faster under anchorage-dependent but not -independent conditions. The in vitro invasion and in vivo metastatic potential of these LNCaP sublines surprisingly correlated with anchorage-dependent and not -independent growth. The derivative LNCaP sublines when cultured in vitro produced a substantially higher (20-30-fold) amount of basal steady-state concentrations of PSA than that of the parental LNCaP cells. PSA production was high initially, but was markedly reduced when the derivative cell lines were inoculated and allowed to grow long-term in vivo for the establishment of tumors and metastasis, suggesting that unknown host factors derived either from the prostate or the bone can effectively downregulate PSA expression by prostate tumor epithelium.
Conclusions: The LNCaP model of human prostate cancer progression will help improve our understanding of the mechanisms of androgen-independence and osseous metastasis, and tumor-host determinants of PSA expression.
Copyright 2000 Wiley-Liss, Inc.
Similar articles
- Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Wu HC, et al. Int J Cancer. 1994 May 1;57(3):406-12. doi: 10.1002/ijc.2910570319. Int J Cancer. 1994. PMID: 8169003 - Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Thalmann GN, et al. Cancer Res. 1994 May 15;54(10):2577-81. Cancer Res. 1994. PMID: 8168083 - Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW. Wu TT, et al. Int J Cancer. 1998 Sep 11;77(6):887-94. doi: 10.1002/(sici)1097-0215(19980911)77:6<887::aid-ijc15>3.0.co;2-z. Int J Cancer. 1998. PMID: 9714059 - Human prostate cancer progression models and therapeutic intervention.
Chung LW, Kao C, Sikes RA, Zhau HE. Chung LW, et al. Hinyokika Kiyo. 1997 Nov;43(11):815-20. Hinyokika Kiyo. 1997. PMID: 9436028 Review. - Establishment of human prostate carcinoma skeletal metastasis models.
Zhau HE, Li CL, Chung LW. Zhau HE, et al. Cancer. 2000 Jun 15;88(12 Suppl):2995-3001. doi: 10.1002/1097-0142(20000615)88:12+<2995::aid-cncr15>3.3.co;2-p. Cancer. 2000. PMID: 10898343 Review.
Cited by
- Goserelin loaded nanoparticles inhibit growth and induce apoptosis in human prostate cancer cell lines.
Tomar P, Jain N, Agarwal GS, Dixit VK. Tomar P, et al. Drug Deliv Transl Res. 2012 Aug;2(4):265-71. doi: 10.1007/s13346-012-0082-2. Drug Deliv Transl Res. 2012. PMID: 25787032 - Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions.
Decker KF, Zheng D, He Y, Bowman T, Edwards JR, Jia L. Decker KF, et al. Nucleic Acids Res. 2012 Nov;40(21):10765-79. doi: 10.1093/nar/gks888. Epub 2012 Sep 27. Nucleic Acids Res. 2012. PMID: 23019221 Free PMC article. - Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.
Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, Lin SH. Yu-Lee LY, et al. Cancer Res. 2018 Jun 1;78(11):2911-2924. doi: 10.1158/0008-5472.CAN-17-1051. Epub 2018 Mar 7. Cancer Res. 2018. PMID: 29514796 Free PMC article. - Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Chou YW, Chaturvedi NK, Ouyang S, Lin FF, Kaushik D, Wang J, Kim I, Lin MF. Chou YW, et al. Cancer Lett. 2011 Dec 8;311(2):177-86. doi: 10.1016/j.canlet.2011.07.015. Epub 2011 Jul 22. Cancer Lett. 2011. PMID: 21862211 Free PMC article. - MicroRNA-1205 Regulation of FRYL in Prostate Cancer.
Naidoo M, Levine F, Gillot T, Orunmuyi AT, Olapade-Olaopa EO, Ali T, Krampis K, Pan C, Dorsaint P, Sboner A, Ogunwobi OO. Naidoo M, et al. Front Cell Dev Biol. 2021 Jul 27;9:647485. doi: 10.3389/fcell.2021.647485. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34386489 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous